Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
ASCO 2024: Latest Data in Melanoma
Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.
Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.
Dr Lipson provides insights surrounding combination therapies in melanoma management.
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
3
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
4
Counseling Patients With OSA on Side Effects of GLP-1s: Matthew Biszewski, PharmD
5
